Clinical Trials with Oncolytic Adenovirus in China
Abstract
Since the 1990s, oncolytic viruses were utilized to treat cancer patients from phase I to phase III. Oncolytic virus development in China has been keeping in step with that in other countries and even accelerated the process in some fields, especially in conducting clinical trials. H101 is one kind of oncolytic adenovirus with E1B-55KD and partial E3 deleted developed by Shanghai Sunwaybio. From 2000-2004, phase I to phase III clinical trials for treating head and neck cancer were conducted in China. Clinical data show that H101 is well tolerable and has good efficacy when combined with chemotherapy in some cancer treatment modalities. We review the clinical results and relative issues of H101 in treating cancer and discuss approaches and possible improvements for the future. Information on other oncolytic viruses developing in China is also provided.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Many oncolytic viruses have been tested in clinical trials, with one licensed in China.
“Many oncolytic viruses have been tested in clinical trials, 66 with one of them licensed in China.67”
From CRISPR-Cas9: a new and promising player in gene therapy (2015) · cites this paper as [67]
The citation lists haven’t been fetched yet
References 42 · Cited by 274
- Authors
- Yu, W., & Fang, H.
- Venue
- Current Cancer Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2007-03-01
- Volume
- 7
- Issue
- 2
- Pages
- 141-148
- ISSN
- 1568-0096 (ISSN-L)
- OpenAlex
- W2162350300
- Cited by
- 274
- References
- 42
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 4 · 2023: 8 · 2022: 14 · 2021: 14 · 2020: 7 · 2019: 8 · 2018: 10 · 2017: 9 · 2016: 16 · 2015: 20 · 2014: 15 · 2013: 19 · 2012: 21
- FWCI
- 12.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Cancer Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
- Keywords
- oncolytic adenovirus, H101, oncolytic virotherapy, head and neck cancer, combination with chemotherapy, clinical trial results, tolerability
- MeSH terms
- Adenoviridae, Adult, Aged, China, Clinical Trials as Topic, Combined Modality Therapy, Female, Head and Neck Neoplasms, Humans, Male, Middle Aged, Research Design, Virus Replication, Treatment Outcome, Adenovirus E1B Proteins, Adenovirus E3 Proteins, Oncolytic Virotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
